文献速递甲状腺疾病

COVID-19大流行对不确定性甲状腺结节手术的影响(THYCOVID):一项回顾性、国际性、多中心、横断面研究

Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2023-04-28

这项回顾性国际多中心横断面研究纳入157个中心、49个国家的87467例甲状腺手术患者,其中22974例因不确定性甲状腺结节手术。大流行升级期每中心每月手术中位数较大流行前和大流行下降期显著减少。与大流行前相比,大流行下降期甲状腺肿瘤大于10mm、淋巴结转移和高结构性疾病复发风险肿瘤的发生率增加。作者认为手术减少可能致侵袭性甲状腺肿瘤增多,但需考虑其他假说,并建议不确定性甲状腺结节手术不应再推迟。

要点

  • 大流行升级期不确定性甲状腺结节手术量较前显著减少。
  • 大流行下降期较大肿瘤、淋巴结转移和高复发风险肿瘤发生率增加。
  • 作者建议不确定性甲状腺结节手术即使在大流行升级期也不再推迟。

核心结论

  • 研究提示COVID-19大流行期间不确定性甲状腺结节手术减少可能致侵袭性甲状腺肿瘤发生增加。
  • 应考虑其他假说,包括该时期侵袭性恶性肿瘤患者选择增加。
  • 作者建议不确定性甲状腺结节手术即使在未来大流行升级时也不再推迟。

研究设计与样本

  • 回顾性、国际性、多中心、横断面研究,中心于2022年6月22日受邀参与。
  • 各中心提供2019年1月1日至2021年12月31日连续行甲状腺手术患者的病历数据。
  • 不确定性甲状腺结节患者按手术时间分三组:2019年1月1日至2020年2月29日(全球大流行前阶段)、2020年3月1日至2021年5月31日(大流行升级阶段)、2021年6月1日至12月31日(大流行下降阶段)。
  • 共收集157个中心(49个国家)87467例因良恶性甲状腺疾病手术患者数据,其中22974例因不确定性甲状腺结节手术(女性18052例[78.6%],男性4922例[21.4%])。
  • 研究注册于ClinicalTrials.gov,NCT05178186。

主要发现

  • 大流行升级期每中心每月手术中位数1.4(IQR 0.6-3.4)较大流行前2.0(0.9-3.7)显著减少(p<0.0001),较大流行下降期2.3(1.0-5.0)显著减少(p<0.0001)。
  • 与大流行前相比,大流行下降期甲状腺肿瘤大于10mm发生率增加:2554/3704(69.0%)vs 1515/2119(71.5%),OR 1.1(95%CI 1.0-1.3),p=0.042。
  • 与大流行前相比,大流行下降期淋巴结转移发生率增加:343/(9.3%)vs 264/(12.5%),OR 1.4(95%CI 1.2-1.7),p=0.0001。
  • 与大流行前相比,大流行下降期高结构性疾病复发风险肿瘤发生率增加:203/3584(5.7%)vs 155/2006(7.7%),OR 1.4(95%CI 1.1-1.7),p=0.0039。

临床怎么用

  • 作者建议不确定性甲状腺结节手术即使在未来大流行升级时也不再推迟。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. METHODS: In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. FINDINGS: Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p<0·0001) and pandemic decrease phase (2·3 [1·0-5·0]; p<0·0001). Compared with the prepandemic phase, in the pandemic decrease phase we observed an increased occurrence of thyroid tumours larger than 10 mm (2554 [69·0%] of 3704 vs 1515 [71·5%] of 2119; OR 1·1 [95% CI 1·0-1·3]; p=0·042), lymph node metastases (343 [9·3%] vs 264 [12·5%]; OR 1·4 [1·2-1·7]; p=0·0001), and tumours at high risk of structural disease recurrence (203 [5·7%] of 3584 vs 155 [7·7%] of 2006; OR 1·4 [1·1-1·7]; p=0·0039). INTERPRETATION: Our study suggests that the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic period could have led to an increased occurrence of aggressive thyroid tumours. However, other compelling hypotheses, including increased selection of patients with aggressive malignancies during this period, should be considered. We suggest that surgery for indeterminate thyroid nodules should no longer be postponed even in future instances of pandemic escalation. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Medas F, Dobrinja C, Al-Suhaimi EA, et al. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study. Lancet Diabetes Endocrinol. 2023. PMID: 37127041. doi:10.1016/S2213-8587(23)00094-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。